Pharmacodynamic and Clinical Outcome Study of Mongersen in Patients With Crohn's Disease
- First Posted Date
- 2016-02-19
- Last Posted Date
- 2018-08-14
- Lead Sponsor
- Celgene
- Target Recruit Count
- 18
- Registration Number
- NCT02685683
- Locations
- 🇮🇹
Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
🇮🇹Policlinico Tor Vergata, Rome, Italy
A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2016-02-19
- Last Posted Date
- 2023-10-06
- Lead Sponsor
- Celgene
- Target Recruit Count
- 56
- Registration Number
- NCT02685826
- Locations
- 🇺🇸
Swedish Medical Center, Seattle, Washington, United States
🇨🇦Cross Cancer Institute, Edmonton, Alberta, Canada
🇨🇦British Columbia Cancer Agency, Vancouver, British Columbia, Canada
A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2016-02-09
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- Celgene
- Target Recruit Count
- 130
- Registration Number
- NCT02677922
- Locations
- 🇮🇹
Local Institution - 250, Pesaro, Italy
🇪🇸Local Institution - 381, Madrid, Spain
🇪🇸Local Institution - 380, Malaga, Spain
A Study to Assess Clinical an Patient Reported Outcomes With Nab-paclitaxel in Combination With Gemcitabine in Route Clinical Practice Treating Pancreatic Cancer
- Conditions
- First Posted Date
- 2016-02-02
- Last Posted Date
- 2019-09-16
- Lead Sponsor
- Celgene
- Target Recruit Count
- 44
- Registration Number
- NCT02670746
- Locations
- 🇳🇱
Gelderse Vallei, Ede, North Brabant, Netherlands
🇳🇱LUMC, Leiden, South-Holland, Netherlands
🇳🇱Spaarne Gasthuis, Haarlem, North Holland, Netherlands
Study of bb2121 in Multiple Myeloma
- First Posted Date
- 2016-01-20
- Last Posted Date
- 2023-01-23
- Lead Sponsor
- Celgene
- Target Recruit Count
- 67
- Registration Number
- NCT02658929
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸National Cancer Institute, Bethesda, Maryland, United States
🇺🇸Stanford Cancer Center, Stanford, California, United States
Study of Nab-paclitaxel (Abraxane®) Treatment in Patients With Metastatic Breast Cancer in Routine Clinical Practice
- Conditions
- First Posted Date
- 2016-01-13
- Last Posted Date
- 2016-11-01
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 46
- Registration Number
- NCT02655159
- Locations
- 🇪🇸
Complejo Hospitalario Jaén, Jaén, Andalucía, Spain
🇪🇸Hospital Clínico Lozano Blesa, Zaragoza, Aragón, Spain
🇪🇸Hospital Navarra, Pamplona, Navarra, Spain
A Long-term Active Treatment Study of Mongersen (GED-0301) in Subjects With Crohn's Disease
- First Posted Date
- 2015-12-29
- Last Posted Date
- 2019-01-29
- Lead Sponsor
- Celgene
- Target Recruit Count
- 310
- Registration Number
- NCT02641392
- Locations
- 🇦🇺
Liverpool Hospital, Liverpool, New South Wales, Australia
🇷🇸Military Medical Academy, Belgrade, Serbia
🇬🇧John Radcliffe Hospital, Oxford, United Kingdom
A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS)
- Conditions
- Interventions
- First Posted Date
- 2015-12-29
- Last Posted Date
- 2018-10-18
- Lead Sponsor
- Celgene
- Target Recruit Count
- 28
- Registration Number
- NCT02641002
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Mayo Clinic Phoenix, Phoenix, Arizona, United States
Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer
- First Posted Date
- 2015-12-18
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Celgene
- Target Recruit Count
- 17
- Registration Number
- NCT02635061
- Locations
- 🇺🇸
Local Institution - 350, Boston, Massachusetts, United States
A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes
- First Posted Date
- 2015-12-15
- Last Posted Date
- 2021-12-17
- Lead Sponsor
- Celgene
- Target Recruit Count
- 229
- Registration Number
- NCT02631070
- Locations
- 🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States
🇺🇸H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇩🇪Universitatsklinikum Bonn, Bonn, Germany